Spyre Therapeutics (SYRE) Net Income towards Common Stockholders (2015 - 2026)
Spyre Therapeutics posted quarterly Net Income towards Common Stockholders of -$69.0 million for Q1 2026, down 54.12% year-on-year from -$150.4 million in Q1 2025, and down 10.36% on a QoQ basis from -$62.5 million in Q4 2025.
Spyre Therapeutics (SYRE) has 12 years of Net Income towards Common Stockholders data on file, last reported at -$69.0 million in Q1 2026.
- For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 54.12% year-over-year to -$69.0 million; the trailing twelve-month figure through Mar 2026 stood at -$179.4 million (up 14.12% YoY), and the FY2025 full-year result was -$155.2 million, up 25.39% from the prior year.
- Net Income towards Common Stockholders for Q1 2026 stood at -$69.0 million, down from -$62.5 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$11.2 million in Q3 2025 and bottomed at -$217.1 million in Q2 2023.
- The 5-year median for Net Income towards Common Stockholders is -$40.1 million (2023), against an average of -$50.3 million.
- The widest annual swing landed in 2023, when Net Income towards Common Stockholders tumbled 872.45%; it then surged 83.8% in 2025.
- A 5-year view of Net Income towards Common Stockholders shows it stood at -$18.8 million in 2022, then sank by 235.67% to -$63.2 million in 2023, then climbed by 10.9% to -$56.3 million in 2024, then slipped by 11.07% to -$62.5 million in 2025, then declined by 10.36% to -$69.0 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$69.0 million (Q1 2026), -$62.5 million (Q4 2025), and -$11.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -13.56 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 2.50 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.63 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Spyre Therapeutics | 5.55 Bn | 5.55 Bn | - | -69.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -69.01 Mn |
| Dec 31, 2025 | -62.53 Mn |
| Sep 30, 2025 | -11.18 Mn |
| Jun 30, 2025 | -36.72 Mn |
| Mar 31, 2025 | -44.77 Mn |
| Dec 31, 2024 | -56.30 Mn |
| Sep 30, 2024 | -69.03 Mn |
| Jun 30, 2024 | -38.84 Mn |
| Mar 31, 2024 | -43.86 Mn |
| Dec 31, 2023 | -63.18 Mn |
| Sep 30, 2023 | -40.11 Mn |
| Jun 30, 2023 | -217.08 Mn |
| Mar 31, 2023 | -18.42 Mn |
| Dec 31, 2022 | -18.82 Mn |
| Sep 30, 2022 | -18.23 Mn |
| Jun 30, 2022 | -22.32 Mn |
| Mar 31, 2022 | -24.44 Mn |
| Dec 31, 2021 | -20.45 Mn |
| Sep 30, 2021 | -20.31 Mn |
| Jun 30, 2021 | -6.83 Mn |
| Mar 31, 2021 | -18.19 Mn |
| Dec 31, 2020 | -22.71 Mn |
| Sep 30, 2020 | -18.03 Mn |
| Jun 30, 2020 | -21.42 Mn |
| Mar 31, 2020 | -18.72 Mn |
| Dec 31, 2019 | -21.48 Mn |
| Sep 30, 2019 | -21.56 Mn |
| Jun 30, 2019 | -18.00 Mn |
| Mar 31, 2019 | -17.15 Mn |
| Dec 31, 2018 | -14.88 Mn |
| Sep 30, 2018 | -11.90 Mn |
| Jun 30, 2018 | -9.41 Mn |
| Mar 31, 2018 | -8.10 Mn |
| Dec 31, 2017 | -6.48 Mn |
| Sep 30, 2017 | -7.86 Mn |
| Jun 30, 2017 | -6.62 Mn |
| Mar 31, 2017 | -6.24 Mn |
| Dec 31, 2016 | -5.48 Mn |
| Sep 30, 2016 | -6.24 Mn |
| Jun 30, 2016 | -5.43 Mn |
| Mar 31, 2016 | -4.55 Mn |
| Dec 31, 2015 | -3.99 Mn |
| Sep 30, 2015 | -3.41 Mn |
| Jun 30, 2015 | -1.43 Mn |
| Mar 31, 2015 | -2.70 Mn |